Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Perrone

Showing results (111-120 of 272) with videos related to

Pageof 28
Sort By:
American Journal of Hematology|May 31, 2007
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemiaGiovanni D'Arena, Michela Tarnani, Carlo Rumi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 11, 2013
Pharmacokinetic evaluation of capecitabine in breast cancerGennaro Daniele, Marianna Gallo, Maria Carmela Piccirillo, et al.
Analytical Cellular Pathology (Amsterdam)|January 13, 2017
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based ChemotherapyErnesta Cavalcanti, Vittoria Barchiesi, Dionigio Cerasuolo, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2008
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patientsCesare Gridelli, Ermelinda De Maio, Santi Barbera, et al.
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Critical Reviews in Oncology/Hematology|April 29, 2014
Treatment of small cell lung cancerAlessandro Morabito, Guido Carillio, Gennaro Daniele, et al.
Tumori|November 10, 2005
Cost of insurance policies for investigator-initiated cancer clinical trials in ItalyFrancesco Perrone, Maurizio Marangolo, Francesco Di Costanzo, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Pageof 28

Showing results (111-120 of 272) with videos related to

Sort By:
Pageof 28
American Journal of Hematology|May 31, 2007
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemiaGiovanni D'Arena, Michela Tarnani, Carlo Rumi, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2008
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trialVittorio Gebbia, Cesare Gridelli, Claudio Verusio, et al.
Expert Opinion on Drug Metabolism & Toxicology|January 11, 2013
Pharmacokinetic evaluation of capecitabine in breast cancerGennaro Daniele, Marianna Gallo, Maria Carmela Piccirillo, et al.
Analytical Cellular Pathology (Amsterdam)|January 13, 2017
Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based ChemotherapyErnesta Cavalcanti, Vittoria Barchiesi, Dionigio Cerasuolo, et al.
Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2008
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patientsCesare Gridelli, Ermelinda De Maio, Santi Barbera, et al.
The Oncologist|April 8, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directionsAlessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, et al.
Critical Reviews in Oncology/Hematology|April 29, 2014
Treatment of small cell lung cancerAlessandro Morabito, Guido Carillio, Gennaro Daniele, et al.
Tumori|November 10, 2005
Cost of insurance policies for investigator-initiated cancer clinical trials in ItalyFrancesco Perrone, Maurizio Marangolo, Francesco Di Costanzo, et al.
Expert Review of Anticancer Therapy|October 19, 2013
Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectivesRaffaele Costanzo, Agnese Montanino, Massimo Di Maio, et al.
Pageof 28